Microbiologic findings and correlations with serum tumor necrosis factor-α in patients with severe sepsis and septic shock

被引:84
作者
Cohen, J
Abraham, E
机构
[1] Hammersmith Hosp, Imperial Coll, Sch Med, Dept Infect Dis, London W12 0NN, England
[2] Univ Colorado, Hlth Sci Ctr, Div Pulm Sci Crit Care Med, Denver, CO USA
关键词
D O I
10.1086/314839
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To understand the microbiology of sepsis and its relationship with tumor necrosis factor (TNF)-alpha: 444 septic patients were studied in a phase II clinical trial. In total, 270 (61%) 444 of episodes were microbiologically documented. The most common isolates were Escherichia coli, Staphylococcus aureus, and Streptococcus pneumoniae. In some patients, obligate anaerobes were isolated in pure culture. Data on baseline TNF-alpha (n = 409) showed that the geometric mean TNF-alpha concentrations in patients with severe sepsis and in those with late shock were 41 pg/mL (range, 5-3310) and 58 pg/mL (range, 5-1870), respectively. Patients with a positive culture had significantly higher TNF-alpha levels (65.9 vs. 29.2 pg/mL, P = .0001). Patients with a pure gram-negative infection had significantly higher TNF-alpha levels than those with a pure gram-positive or mixed infection, especially in the late shock group (142.6, 64.0, and 52.8 pg/mL, respectively, P = .004). These results provide further support for the concept that patients with sepsis are a heterogeneous group that require more precise definition.
引用
收藏
页码:116 / 121
页数:6
相关论文
共 19 条
[1]   EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL [J].
ABRAHAM, E ;
WUNDERINK, R ;
SILVERMAN, H ;
PERL, TM ;
NASRAWAY, S ;
LEVY, H ;
BONE, R ;
WENZEL, RP ;
BALK, R ;
ALLRED, R ;
PENNINGTON, JE ;
WHERRY, JC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12) :934-941
[2]   p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock - A randomized controlled multicenter trial [J].
Abraham, E ;
Glauser, MP ;
Butler, T ;
Garbino, J ;
Gelmont, D ;
Laterre, PF ;
Kudsk, K ;
Bruining, HA ;
Otto, C ;
Tobin, E ;
Zwingelstein, C ;
Lesslauer, W ;
Leighton, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (19) :1531-1538
[3]   The effects of ibuprofen on the physiology and survival of patients with sepsis [J].
Bernard, GR ;
Wheeler, AP ;
Russell, JA ;
Schein, R ;
Summer, WR ;
Steinberg, KP ;
Fulkerson, WJ ;
Wright, PE ;
Christman, BW ;
Dupont, WD ;
Higgins, SB ;
Swindell, BB .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (13) :912-918
[4]   Bacteremia and severe sepsis in adults: A multicenter prospective survey in ICUs and wards of 24 hospitals [J].
BrunBuisson, C ;
Doyon, F ;
Carlet, J ;
Bedock, B ;
Annonay, CH ;
Valente, E ;
Lescale, O ;
Misset, B ;
Charbonneau, P ;
Vergnaud, M ;
Cohen, R ;
Coloignier, M ;
Frances, JL ;
Combes, A ;
Duval, O ;
Dellamonica, P ;
Descamps, JM ;
Domart, Y ;
Galiacy, JL ;
Gouin, F ;
Guivarch, G ;
Hennequin, C ;
Krajevitch, A ;
Delmas, P ;
Holzapfel, L ;
Lepeu, G ;
Loirat, P ;
Thaler, F ;
Knani, L ;
Mercier, JC ;
Mouton, Y ;
Libbrecht, E ;
Offenstadt, G ;
Pinaud, M ;
Pinsart, M ;
Girou, E ;
Portier, H ;
Grappin, M ;
Rebeix, MT ;
Regnier, B ;
Gachot, B ;
Ricome, JL ;
Sollet, JP ;
Mentec, H ;
Tempelhoff, G ;
Beuret, P ;
Lepoutre, A .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 154 (03) :617-624
[5]   INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis [J].
Cohen, J ;
Carlet, J .
CRITICAL CARE MEDICINE, 1996, 24 (09) :1431-1440
[6]   PROTECTIVE EFFECT OF 55-KD BUT NOT 75-KD SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTOR IMMUNOGLOBULIN-G FUSION PROTEINS IN AN ANIMAL-MODEL OF GRAM-NEGATIVE SEPSIS [J].
EVANS, TJ ;
MOYES, D ;
CARPENTER, A ;
MARTIN, R ;
LOETSCHER, H ;
LESSLAUER, W ;
COHEN, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (06) :2173-2179
[7]   Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein [J].
Fisher, CJ ;
Agosti, JM ;
Opal, SM ;
Lowry, SF ;
Balk, RA ;
Sadoff, JC ;
Abraham, E ;
Schein, RMH ;
Benjamin, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (26) :1697-1702
[8]   RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST IN THE TREATMENT OF PATIENTS WITH SEPSIS SYNDROME - RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
FISHER, CJ ;
DHAINAUT, JFA ;
OPAL, SM ;
PRIBBLE, JP ;
BALK, RA ;
SLOTMAN, GJ ;
IBERTI, TJ ;
RACKOW, EC ;
SHAPIRO, MJ ;
GREENMAN, RL ;
REINES, HD ;
SHELLY, MP ;
THOMPSON, BW ;
LABRECQUE, JF ;
CATALANO, MA ;
KNAUS, WA ;
SADOFF, JC ;
ASTIZ, M ;
CARPATI, C ;
BONE, RC ;
FREIDMAN, B ;
MURE, AJ ;
BRATHWAITE, C ;
SHAPIRO, E ;
MELHORN, L ;
TAYLOR, R ;
KEEGAN, M ;
OBRIEN, J ;
SCHEIN, R ;
PENA, M ;
WASSERLOUF, M ;
OROPELLO, J ;
BENJAMIN, E ;
DELGUIDICE, R ;
EMMANUEL, G ;
LIE, T ;
ANDERSON, L ;
MARSHALL, J ;
DEMAJO, W ;
ROTSTEIN, O ;
FOSTER, D ;
ABRAHAM, E ;
MIDDLETON, H ;
PERRY, C ;
LEVY, H ;
FRY, DE ;
SIMPSON, SQ ;
CROWELL, RE ;
NEIDHART, M ;
STEVENS, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (23) :1836-1843
[9]   CLINICAL AND MICROBIOLOGICAL CHARACTERISTICS OF SEVERE GROUP-A STREPTOCOCCUS INFECTIONS AND STREPTOCOCCAL TOXIC SHOCK SYNDROME [J].
FORNI, AL ;
KAPLAN, EL ;
SCHLIEVERT, PM ;
ROBERTS, RB .
CLINICAL INFECTIOUS DISEASES, 1995, 21 (02) :333-340
[10]   THE CLINICAL-EVALUATION OF NEW DRUGS FOR SEPSIS - A PROSPECTIVE-STUDY DESIGN BASED ON SURVIVAL ANALYSIS [J].
KNAUS, WA ;
HARRELL, FE ;
FISHER, CJ ;
WAGNER, DP ;
OPAL, SM ;
SADOFF, JC ;
DRAPER, EA ;
WALAWANDER, CA ;
CONBOY, K ;
GRASELA, TH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (10) :1233-1241